Flyer

Health Science Journal

  • ISSN: 1108-7366
  • Journal h-index: 51
  • Journal CiteScore: 10.69
  • Journal Impact Factor: 9.13
  • Average acceptance to publication time (5-7 days)
  • Average article processing time (30-45 days) Less than 5 volumes 30 days
    8 - 9 volumes 40 days
    10 and more volumes 45 days
Awards Nomination 20+ Million Readerbase
Indexed In
  • Genamics JournalSeek
  • China National Knowledge Infrastructure (CNKI)
  • CiteFactor
  • CINAHL Complete
  • Scimago
  • Electronic Journals Library
  • Directory of Research Journal Indexing (DRJI)
  • EMCare
  • OCLC- WorldCat
  • University Grants Commission
  • Geneva Foundation for Medical Education and Research
  • Euro Pub
  • Google Scholar
  • SHERPA ROMEO
  • Secret Search Engine Labs
Share This Page

David Britez

Department of Health and communication, Egypt

Publications
  • Research Article   
    Detailed Information on Metabolic-Associated Fatty Liver Disease Involvement
    Author(s): David Britez* and Craig Venter

    Metabolic-Associated Fatty Liver Disease (MAFLD), formerly known as Non-Alcoholic Fatty Liver Disease (NAFLD), is a condition characterized by the accumulation of fat in the liver. It is strongly associated with metabolic syndrome, which includes obesity, insulin resistance, dyslipidemia, and hypertension. MAFLD has emerged as the most common cause of chronic liver disease worldwide. The relationship between MAFLD and diabetes is bidirectional and complex. Diabetes is a well-established risk factor for the development and progression of MAFLD. Insulin resistance, a hallmark of type 2 diabetes, plays a crucial role in the pathogenesis of MAFLD. When cells become resistant to the effects of insulin, the pancreas compensates by producing more insulin. This excess insulin promotes lipid accumulation in the liver, leading to the development of MAFLD... View More»

    DOI: 10.36648/1791- 809X.17.5.1020

    Abstract HTML PDF